

Chemring

Flight path adjusted

Chemring is making strong progress on many fronts as market dynamics begin to play in its favour. It has re-established its financial footing and is positioned to drive growth organically and with selective M&A. FY18 is likely to be one of consolidation due to the profile of the 40mm ammunition contracts, but earnings growth anticipated in Countermeasures and Sensors offsets a fall in Energetics. The operational excellence programme targets a 300bp improvement on existing product lines by 2022.

FY17 results show momentum

Reported FY17 revenue of £547.5m (FY16 £477.1m) was announced in the preclose statement, reflecting 11% organic constant currency growth. Revenues at Countermeasures and Sensors both marginally declined on plant closure and programme refocus respectively. Revenue growth of 32% at Energetics was largely due to large ammunition contracts from Middle Eastern customers. Underlying EBITDA was up 9% organically at £81m (FY16 £73.8m) and underlying profit improved in each of the three divisions. Reported group PBT was £44.1m (£34.0m) with underlying EPS of 12.9p. Cash generation was encouraging with net debt falling to £80m, a net debt/EBITDA of 0.99x compared to less than 1.50x targeted.

Looking forward

Chemring indicates an improving market backdrop. Order cover for FY18 is 70% and the year is expected to be second half-weighted, as in prior years. Stronger conventional and SMD flare demand should benefit Countermeasures. Sensors may also see an improvement with awards at Roke and HMDS. Energetics should reflect the expected fall in 40mm ammunition volumes. Underpinning divisional performance, Chemring is in much improved financial health and demonstrates a clearer approach to capital allocation. We believe that the Operational Excellence Programme will continue to deliver benefits. The company expects group operating margin to increase by 75bps in FY18 and by 300bp by 2022. Progress is supported by the company's ability to make sensible capital allocation decisions and invest in growth. In combination, we believe the operational excellence programme should augment results as improving market demand drives orders.

Valuation: Return to normality

It is possible that earnings consensus may improve following delivery of these results. Chemring is currently trading on 14.5x FY18e consensus EPS falling to 13.6x FY19e which represents a modest premium to peers. The self-determination afforded by the resolution of the debt constraint warrants increasing optimism.

Consensus estimates						
Year end	Revenue (£m)	PBT (£m)	EPS (p)	DPS (p)	P/E (x)	Yield (%)
10/16	477.1	34.0	10.30	1.30	17.3	0.7
10/17	547.5	44.1	12.90	3.00	13.8	1.7
10/18e	517.3	44.2	12.30	3.30	14.5	1.9
10/19e	530.5	48.4	13.60	3.50	13.1	2.0


Source: Bloomberg

Aerospace & defence

18 January 2018

Price 178.2p Market cap £498m

US\$1.39/£1



Share details Code CHG Listing LSE Shares in issue 279.2m

Business description

Chemring is a global leader in aircraft and naval countermeasures, sensors and electronics, and other energetic materials for military use in training, peacekeeping and conflict. Its operations in the US, UK, Norway and Australia supply home governments, NATO and the Middle East.

Rull

- Leading market position in growing defence spending climate
- Organic and M&A growth potential supported by robust balance sheet
- Operational Excellence Programme driving improvement across all areas

Bear

- SFO investigation into specific historic contracts at CTSL
- Order timing subject to budgetary pressures
- Further loan note payments required (£63m)

Analysts

Andy Chambers +44 (0)20 3681 2525 Annabel Hewson +44 (0)20 3077 5700

industrials@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc. (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research was not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Ply Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Ply Ltd (AFSL: 42744)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the Dintel States by Edison Unaiper Use Institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reliable information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Francial Advisers Act 2008 (FAA) (as described in sections 5 (1) (1) (a) (a) of (c) of the FAA). This is not a solicitation or i